GreenLight HPS™ 120‐W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2‐year randomized double‐blind prospective urodynamic investigation
Study Type – Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower LUTS caused by BPH. The learning curve for PVP is short and the main advantages of this m...
Saved in:
| Published in | BJU international Vol. 110; no. 8; pp. 1184 - 1189 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.10.2012
Wiley-Blackwell |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1464-4096 1464-410X 1464-410X |
| DOI | 10.1111/j.1464-410X.2011.10878.x |
Cover
| Abstract | Study Type – Therapy (RCT)
Level of Evidence 1b
What's known on the subject? and What does the study add?
Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower LUTS caused by BPH. The learning curve for PVP is short and the main advantages of this method over TURP are a shorter period of hospitalization, a shorter period of postoperative vesical catheterization, lower levels of retrograde ejaculation, rare development of dilutional hyponatraemia syndrome, the lack of a need for postoperative vesical irrigation as a result of extremely low indices of postoperative haematuria, and the lack of a need to suspend anticoagulant medication for the surgery. Traditionally, comparisons of the effectiveness of TURP vs PVP have involved parameters such as peak flow urinary rate and post‐void residual urine volume measurements, and have employed questionnaires such as the IPSS and the International Index of Erectile Function instruments. However, studies evaluating detailed urodynamic parameters remain scarce and non‐comparative
The present study compared postoperative, medium‐term urodynamic parameters among patients receiving TURP and high‐power PVP. We consider the present study to be distinctive because it involved a double‐blind, detailed functional analysis of the vesical emptying stage over the course of 2 years, and did not simply comprise an evaluation of clinical parameters and uroflowmetrics. We saw a reduction of infravesical obstruction, as shown by the significant reduction of ≥20 cm H2O in the mean micturition pressure for the groups studied, as well as a significant reduction in bladder outlet obstruction index. Thus, the present data show that high‐power PVP can achieve and maintain the same results as TURP over a period of 24 months regarding an aspect that is particularly important for maintaining vesical health (i.e. detrusor pressure during the evacuation of the bladder). Such urodynamic data describing the functional outcome of PVP are currently missing from the literature.
OBJECTIVE
•
To assess the impact of GreenLight HPSTM 120‐W (American Medical System Incorporation, Minnetonka, MN, USA) laser photovaporization of the prostate (PVP) compared to transurethral resection of the prostate (TURP) on urodynamic results, voiding function and sexual function.
PATIENTS AND METHODS
•
In total, 20 men with intermediate/severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH) were randomly selected and equally divided into two groups: TURP and PVP.
•
Urodynamic evaluation was performed and International Prostate Symptom Score (IPSS), International Index of Erectile Function‐5 and International Consultation on Incontinence Questionnaire – Short Form questionnaires were completed.
•
The results were assessed at 2 years.
RESULTS
•
Mean IPSS scores were reduced in both groups, although they did not differ between the TURP and PVP groups.
•
There was no significant change in International Index of Erectile Function‐5 scores.
•
Half of the patients in the PVP group developed urge urinary incontinence with spontaneous resolution.
•
The urodynamic parameters analyzed showed an improvement for both groups, although the values in the TURP group values were not significantly different from those in the PVP group.
CONCLUSIONS
•
Bladder storage symptoms may represent a major concern, although they are of limited duration in patients undergoing PVP.
•
High‐power PVP can achieve and maintain the same results as TURP over a period of 24 months. |
|---|---|
| AbstractList | What's known on the subject? and What does the study add? Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower LUTS caused by BPH. The learning curve for PVP is short and the main advantages of this method over TURP are a shorter period of hospitalization, a shorter period of postoperative vesical catheterization, lower levels of retrograde ejaculation, rare development of dilutional hyponatraemia syndrome, the lack of a need for postoperative vesical irrigation as a result of extremely low indices of postoperative haematuria, and the lack of a need to suspend anticoagulant medication for the surgery. Traditionally, comparisons of the effectiveness of TURP vs PVP have involved parameters such as peak flow urinary rate and post-void residual urine volume measurements, and have employed questionnaires such as the IPSS and the International Index of Erectile Function instruments. However, studies evaluating detailed urodynamic parameters remain scarce and non-comparative The present study compared postoperative, medium-term urodynamic parameters among patients receiving TURP and high-power PVP. We consider the present study to be distinctive because it involved a double-blind, detailed functional analysis of the vesical emptying stage over the course of 2 years, and did not simply comprise an evaluation of clinical parameters and uroflowmetrics. We saw a reduction of infravesical obstruction, as shown by the significant reduction of ≥20 cm H(2)O in the mean micturition pressure for the groups studied, as well as a significant reduction in bladder outlet obstruction index. Thus, the present data show that high-power PVP can achieve and maintain the same results as TURP over a period of 24 months regarding an aspect that is particularly important for maintaining vesical health (i.e. detrusor pressure during the evacuation of the bladder). Such urodynamic data describing the functional outcome of PVP are currently missing from the literature.UNLABELLEDWhat's known on the subject? and What does the study add? Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower LUTS caused by BPH. The learning curve for PVP is short and the main advantages of this method over TURP are a shorter period of hospitalization, a shorter period of postoperative vesical catheterization, lower levels of retrograde ejaculation, rare development of dilutional hyponatraemia syndrome, the lack of a need for postoperative vesical irrigation as a result of extremely low indices of postoperative haematuria, and the lack of a need to suspend anticoagulant medication for the surgery. Traditionally, comparisons of the effectiveness of TURP vs PVP have involved parameters such as peak flow urinary rate and post-void residual urine volume measurements, and have employed questionnaires such as the IPSS and the International Index of Erectile Function instruments. However, studies evaluating detailed urodynamic parameters remain scarce and non-comparative The present study compared postoperative, medium-term urodynamic parameters among patients receiving TURP and high-power PVP. We consider the present study to be distinctive because it involved a double-blind, detailed functional analysis of the vesical emptying stage over the course of 2 years, and did not simply comprise an evaluation of clinical parameters and uroflowmetrics. We saw a reduction of infravesical obstruction, as shown by the significant reduction of ≥20 cm H(2)O in the mean micturition pressure for the groups studied, as well as a significant reduction in bladder outlet obstruction index. Thus, the present data show that high-power PVP can achieve and maintain the same results as TURP over a period of 24 months regarding an aspect that is particularly important for maintaining vesical health (i.e. detrusor pressure during the evacuation of the bladder). Such urodynamic data describing the functional outcome of PVP are currently missing from the literature.To assess the impact of GreenLight HPS™ 120-W (American Medical System Incorporation, Minnetonka, MN, USA) laser photovaporization of the prostate (PVP) compared to transurethral resection of the prostate (TURP) on urodynamic results, voiding function and sexual function.OBJECTIVETo assess the impact of GreenLight HPS™ 120-W (American Medical System Incorporation, Minnetonka, MN, USA) laser photovaporization of the prostate (PVP) compared to transurethral resection of the prostate (TURP) on urodynamic results, voiding function and sexual function.In total, 20 men with intermediate/severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH) were randomly selected and equally divided into two groups: TURP and PVP. Urodynamic evaluation was performed and International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 and International Consultation on Incontinence Questionnaire - Short Form questionnaires were completed. The results were assessed at 2 years.PATIENTS AND METHODSIn total, 20 men with intermediate/severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH) were randomly selected and equally divided into two groups: TURP and PVP. Urodynamic evaluation was performed and International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 and International Consultation on Incontinence Questionnaire - Short Form questionnaires were completed. The results were assessed at 2 years.Mean IPSS scores were reduced in both groups, although they did not differ between the TURP and PVP groups. There was no significant change in International Index of Erectile Function-5 scores. Half of the patients in the PVP group developed urge urinary incontinence with spontaneous resolution. The urodynamic parameters analyzed showed an improvement for both groups, although the values in the TURP group values were not significantly different from those in the PVP group.RESULTSMean IPSS scores were reduced in both groups, although they did not differ between the TURP and PVP groups. There was no significant change in International Index of Erectile Function-5 scores. Half of the patients in the PVP group developed urge urinary incontinence with spontaneous resolution. The urodynamic parameters analyzed showed an improvement for both groups, although the values in the TURP group values were not significantly different from those in the PVP group.Bladder storage symptoms may represent a major concern, although they are of limited duration in patients undergoing PVP. High-power PVP can achieve and maintain the same results as TURP over a period of 24 months.CONCLUSIONSBladder storage symptoms may represent a major concern, although they are of limited duration in patients undergoing PVP. High-power PVP can achieve and maintain the same results as TURP over a period of 24 months. Study Type – Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower LUTS caused by BPH. The learning curve for PVP is short and the main advantages of this method over TURP are a shorter period of hospitalization, a shorter period of postoperative vesical catheterization, lower levels of retrograde ejaculation, rare development of dilutional hyponatraemia syndrome, the lack of a need for postoperative vesical irrigation as a result of extremely low indices of postoperative haematuria, and the lack of a need to suspend anticoagulant medication for the surgery. Traditionally, comparisons of the effectiveness of TURP vs PVP have involved parameters such as peak flow urinary rate and post‐void residual urine volume measurements, and have employed questionnaires such as the IPSS and the International Index of Erectile Function instruments. However, studies evaluating detailed urodynamic parameters remain scarce and non‐comparative The present study compared postoperative, medium‐term urodynamic parameters among patients receiving TURP and high‐power PVP. We consider the present study to be distinctive because it involved a double‐blind, detailed functional analysis of the vesical emptying stage over the course of 2 years, and did not simply comprise an evaluation of clinical parameters and uroflowmetrics. We saw a reduction of infravesical obstruction, as shown by the significant reduction of ≥20 cm H2O in the mean micturition pressure for the groups studied, as well as a significant reduction in bladder outlet obstruction index. Thus, the present data show that high‐power PVP can achieve and maintain the same results as TURP over a period of 24 months regarding an aspect that is particularly important for maintaining vesical health (i.e. detrusor pressure during the evacuation of the bladder). Such urodynamic data describing the functional outcome of PVP are currently missing from the literature. OBJECTIVE • To assess the impact of GreenLight HPSTM 120‐W (American Medical System Incorporation, Minnetonka, MN, USA) laser photovaporization of the prostate (PVP) compared to transurethral resection of the prostate (TURP) on urodynamic results, voiding function and sexual function. PATIENTS AND METHODS • In total, 20 men with intermediate/severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH) were randomly selected and equally divided into two groups: TURP and PVP. • Urodynamic evaluation was performed and International Prostate Symptom Score (IPSS), International Index of Erectile Function‐5 and International Consultation on Incontinence Questionnaire – Short Form questionnaires were completed. • The results were assessed at 2 years. RESULTS • Mean IPSS scores were reduced in both groups, although they did not differ between the TURP and PVP groups. • There was no significant change in International Index of Erectile Function‐5 scores. • Half of the patients in the PVP group developed urge urinary incontinence with spontaneous resolution. • The urodynamic parameters analyzed showed an improvement for both groups, although the values in the TURP group values were not significantly different from those in the PVP group. CONCLUSIONS • Bladder storage symptoms may represent a major concern, although they are of limited duration in patients undergoing PVP. • High‐power PVP can achieve and maintain the same results as TURP over a period of 24 months. What's known on the subject? and What does the study add? Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower LUTS caused by BPH. The learning curve for PVP is short and the main advantages of this method over TURP are a shorter period of hospitalization, a shorter period of postoperative vesical catheterization, lower levels of retrograde ejaculation, rare development of dilutional hyponatraemia syndrome, the lack of a need for postoperative vesical irrigation as a result of extremely low indices of postoperative haematuria, and the lack of a need to suspend anticoagulant medication for the surgery. Traditionally, comparisons of the effectiveness of TURP vs PVP have involved parameters such as peak flow urinary rate and post-void residual urine volume measurements, and have employed questionnaires such as the IPSS and the International Index of Erectile Function instruments. However, studies evaluating detailed urodynamic parameters remain scarce and non-comparative The present study compared postoperative, medium-term urodynamic parameters among patients receiving TURP and high-power PVP. We consider the present study to be distinctive because it involved a double-blind, detailed functional analysis of the vesical emptying stage over the course of 2 years, and did not simply comprise an evaluation of clinical parameters and uroflowmetrics. We saw a reduction of infravesical obstruction, as shown by the significant reduction of ≥20 cm H(2)O in the mean micturition pressure for the groups studied, as well as a significant reduction in bladder outlet obstruction index. Thus, the present data show that high-power PVP can achieve and maintain the same results as TURP over a period of 24 months regarding an aspect that is particularly important for maintaining vesical health (i.e. detrusor pressure during the evacuation of the bladder). Such urodynamic data describing the functional outcome of PVP are currently missing from the literature. To assess the impact of GreenLight HPS™ 120-W (American Medical System Incorporation, Minnetonka, MN, USA) laser photovaporization of the prostate (PVP) compared to transurethral resection of the prostate (TURP) on urodynamic results, voiding function and sexual function. In total, 20 men with intermediate/severe lower urinary tract symptoms as a result of benign prostatic hyperplasia (BPH) were randomly selected and equally divided into two groups: TURP and PVP. Urodynamic evaluation was performed and International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 and International Consultation on Incontinence Questionnaire - Short Form questionnaires were completed. The results were assessed at 2 years. Mean IPSS scores were reduced in both groups, although they did not differ between the TURP and PVP groups. There was no significant change in International Index of Erectile Function-5 scores. Half of the patients in the PVP group developed urge urinary incontinence with spontaneous resolution. The urodynamic parameters analyzed showed an improvement for both groups, although the values in the TURP group values were not significantly different from those in the PVP group. Bladder storage symptoms may represent a major concern, although they are of limited duration in patients undergoing PVP. High-power PVP can achieve and maintain the same results as TURP over a period of 24 months. |
| Author | Muller, Valter José Fernandes Krambeck, Renato Lages de Moraes Sousa, Karlo Danilson de Morais Perpétuo, Daniel Vaz, Fernando Pires Lopes‐da‐Silva, Luiz Felipe Pereira‐Correia, João Antonio Santos, João Bosco Pinheiro |
| Author_xml | – sequence: 1 givenname: João Antonio surname: Pereira‐Correia fullname: Pereira‐Correia, João Antonio – sequence: 2 givenname: Karlo Danilson surname: de Moraes Sousa fullname: de Moraes Sousa, Karlo Danilson – sequence: 3 givenname: João Bosco Pinheiro surname: Santos fullname: Santos, João Bosco Pinheiro – sequence: 4 givenname: Daniel surname: de Morais Perpétuo fullname: de Morais Perpétuo, Daniel – sequence: 5 givenname: Luiz Felipe surname: Lopes‐da‐Silva fullname: Lopes‐da‐Silva, Luiz Felipe – sequence: 6 givenname: Renato Lages surname: Krambeck fullname: Krambeck, Renato Lages – sequence: 7 givenname: Valter José Fernandes surname: Muller fullname: Muller, Valter José Fernandes – sequence: 8 givenname: Fernando Pires surname: Vaz fullname: Vaz, Fernando Pires |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26569938$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22257240$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUUtuFDEUtFAQ-cAVkDdIYTGDf_1DKBJEkIBGAgki2Fke-znjkbt7sLuHTFZIcADOwJ5L5SS4O5MgsQJv_ORXVe-5ah_tNG0DCGFKpjSdJ8spFbmYCEo-TRmhdEpJWZTTizto77axc1OTKt9F-zEuCUkPeXYP7TLGsoIJsod-nQSAZubOFx0-fff-6vtPTBm5-vrjI_YqQsBrtWqDu1Sdaxu8jrgLqol9gG4RlMcBIuix1VrcLQCvQhs71QE-fJYnmW_17PFTrDBLihtQASe2aWt3CQabtp97SI25d40ZmatBbA24D63ZNKp2GrtmDbFz5-MC99Fdq3yEB9v7AJ29evnh-HQye3vy-vj5bKLTB8sJqFyoygDnhCmjCNdCMAuCMqq4MCXYPNMF5aALm9ypSKXE3NhMWJ0JXVl-gA6vddNSn_s0X9YuavBeNdD2USa7aVlwXhUJ-nAL7ec1GLkKrlZhI28sToBHW4CKWnmbHNAu_sHlWV5VvEy48hqnkxExgL2FUCKH1OVSDoHKIVw5pC7H1OVFoh79RdWuGw1LaTn_HwJfnIfNPw-WL96cjSX_DVA8zbU |
| CitedBy_id | crossref_primary_10_1007_s00120_012_3087_z crossref_primary_10_1007_s11930_018_0172_3 crossref_primary_10_1016_j_eururo_2013_03_004 crossref_primary_10_1016_j_eururo_2024_04_031 crossref_primary_10_1111_bju_13479 crossref_primary_10_1002_smrj_20 crossref_primary_10_1186_s12894_015_0029_2 crossref_primary_10_1016_j_eururo_2012_04_051 crossref_primary_10_1007_s11934_015_0525_7 crossref_primary_10_1177_1756287216632429 crossref_primary_10_1590_1806_9282_63_11_929 crossref_primary_10_1159_000356991 crossref_primary_10_5534_wjmh_2016_34_2_110 crossref_primary_10_1016_j_eururo_2014_06_017 crossref_primary_10_1007_s10103_015_1721_x crossref_primary_10_1007_s11884_021_00627_2 crossref_primary_10_1089_end_2012_0136 crossref_primary_10_1016_j_urology_2015_06_024 crossref_primary_10_1089_end_2022_0222 crossref_primary_10_1007_s11934_018_0838_4 crossref_primary_10_1016_j_urology_2014_06_027 crossref_primary_10_1007_s00345_015_1635_z crossref_primary_10_1038_nrurol_2014_23 crossref_primary_10_1007_s11884_015_0294_7 crossref_primary_10_1590_1806_9282_2024d708 crossref_primary_10_1016_j_euf_2022_06_007 crossref_primary_10_3109_21681805_2012_759272 crossref_primary_10_1002_lsm_22240 crossref_primary_10_1016_j_purol_2013_10_003 crossref_primary_10_1097_MOU_0000000000000124 crossref_primary_10_1016_j_eururo_2021_04_012 crossref_primary_10_1136_bmjopen_2018_028855 crossref_primary_10_1007_s10103_012_1235_8 crossref_primary_10_1089_end_2015_0202 crossref_primary_10_1007_s12325_017_0504_0 crossref_primary_10_1007_s00120_015_3983_0 crossref_primary_10_1111_j_1464_410X_2012_10354_x crossref_primary_10_1007_s00345_024_05439_7 crossref_primary_10_1007_s00345_014_1437_8 crossref_primary_10_1089_end_2013_0715 crossref_primary_10_1007_s10103_023_03794_2 crossref_primary_10_1089_pho_2016_4237 crossref_primary_10_1016_j_purol_2018_07_287 crossref_primary_10_2147_RRU_S277482 crossref_primary_10_23736_S2724_6051_24_05802_6 crossref_primary_10_1007_s00345_013_1203_3 crossref_primary_10_1016_j_purol_2013_03_021 crossref_primary_10_3389_fsurg_2021_705105 crossref_primary_10_1111_jsm_12044 crossref_primary_10_1007_s00345_024_05332_3 crossref_primary_10_1007_s10103_015_1843_1 crossref_primary_10_4111_icu_2019_60_6_480 crossref_primary_10_1016_j_urology_2012_11_042 crossref_primary_10_1016_j_urology_2023_12_018 crossref_primary_10_1016_j_purol_2020_12_006 crossref_primary_10_1371_journal_pone_0184442 crossref_primary_10_1007_s10103_013_1320_7 crossref_primary_10_1016_j_jval_2015_04_002 crossref_primary_10_1007_s11934_018_0813_0 crossref_primary_10_1007_s11934_013_0351_8 crossref_primary_10_2530_jslsm_jslsm_35_0039 crossref_primary_10_1016_j_jvir_2021_06_019 crossref_primary_10_1097_MOU_0000000000000500 crossref_primary_10_1038_srep23503 crossref_primary_10_1016_j_ucl_2016_04_006 crossref_primary_10_1039_c8pp00409a crossref_primary_10_1007_s00345_013_1103_6 crossref_primary_10_1111_j_1464_410X_2012_10354_2_x |
| Cites_doi | 10.1097/01.ju.0000128803.04158.76 10.1016/j.eururo.2008.05.003 10.1016/j.urology.2007.01.042 10.1016/j.urology.2009.08.015 10.1590/S1677-55382010000200009 10.1016/j.eururo.2005.07.001 10.1111/j.1464-410X.2008.07905.x 10.1016/S0090-4295(94)80170-3 10.1097/01.ju.0000139541.68542.f6 10.1038/sj.pcan.4500949 10.1089/end.2006.20.580 10.1097/01.ju.0000146631.14200.d4 10.1016/j.urology.2007.09.017 10.1002/nau.10066 10.1097/00042307-200401000-00006 10.1097/00042307-200401000-00005 10.1016/j.eururo.2006.08.006 10.1016/S0022-5347(05)67530-1 10.1089/end.2007.0321 10.1016/j.eursup.2007.11.004 10.1016/j.eururo.2011.05.043 10.1007/BF00182664 10.1016/j.eursup.2008.01.014 10.1016/j.eururo.2010.05.026 10.1016/j.eursup.2008.01.013 10.1016/j.eursup.2008.01.016 |
| ContentType | Journal Article |
| Copyright | 2012 BJU INTERNATIONAL 2015 INIST-CNRS 2012 BJU INTERNATIONAL. |
| Copyright_xml | – notice: 2012 BJU INTERNATIONAL – notice: 2015 INIST-CNRS – notice: 2012 BJU INTERNATIONAL. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/j.1464-410X.2011.10878.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 1189 |
| ExternalDocumentID | 22257240 26569938 10_1111_j_1464_410X_2011_10878_x BJU10878 |
| Genre | article Randomized Controlled Trial Journal Article Comparative Study |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY AIQQE CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c4668-ea64a9de3302ada03c442fe4121a34d8ef65c713ec7f096909a4bdf54fc54c9f3 |
| IEDL.DBID | DR2 |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Thu Oct 02 10:53:27 EDT 2025 Thu Apr 03 07:08:23 EDT 2025 Mon Jul 21 09:13:21 EDT 2025 Thu Apr 24 23:44:10 EDT 2025 Wed Oct 01 04:28:53 EDT 2025 Wed Jan 22 16:41:18 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Nephrology photovaporization Surgical resection Transurethral route Urology Vaporization Prospective Urodynamics Randomization Treatment transurethral resection of prostate Surgery Laser GreenLight laser Surgical approach urodynamic Urogenital system Prostate Comparative study |
| Language | English |
| License | CC BY 4.0 2012 BJU INTERNATIONAL. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4668-ea64a9de3302ada03c442fe4121a34d8ef65c713ec7f096909a4bdf54fc54c9f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 22257240 |
| PQID | 1081873397 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1081873397 pubmed_primary_22257240 pascalfrancis_primary_26569938 crossref_primary_10_1111_j_1464_410X_2011_10878_x crossref_citationtrail_10_1111_j_1464_410X_2011_10878_x wiley_primary_10_1111_j_1464_410X_2011_10878_x_BJU10878 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2012 |
| PublicationDateYYYYMMDD | 2012-10-01 |
| PublicationDate_xml | – month: 10 year: 2012 text: October 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd Wiley-Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell |
| References | 2010; 75 2005; 173 2010; 36 2010; 58 1995; 13 2011; 60 2006; 8 1994; 44 2008; 7 2008; 54 2007; 51 2008; 102 2005; 48 2007; 10 2008; 71 2007; 14 2009; 33 2006; 20 2004; 14 2002; 21 2004; 172 2004; 171 2000; 163 2008; 22 2007; 69 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 Matoka DJ (e_1_2_7_30_2) 2007; 14 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_13_2 e_1_2_7_12_2 e_1_2_7_11_2 e_1_2_7_10_2 Manjón CC (e_1_2_7_18_2) 2009; 33 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 Reich O (e_1_2_7_20_2) 2005; 173 Te AE (e_1_2_7_3_2) 2006; 8 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_23_2 e_1_2_7_31_2 e_1_2_7_22_2 e_1_2_7_21_2 |
| References_xml | – volume: 71 start-page: 247 year: 2008 end-page: 51 article-title: Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short‐term prospective randomized trial publication-title: Urology – volume: 54 start-page: 902 year: 2008 end-page: 10 article-title: Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow‐up publication-title: Eur Urol – volume: 21 start-page: 261 year: 2002 end-page: 74 article-title: Good urodynamic practices: uroflowmetry, filling cystometry, and pressure‐flow studies publication-title: Neurourol Urodyn – volume: 171 start-page: 2502 year: 2004 end-page: 4 article-title: Experimental comparison of high‐power (80W) potassiumtitanyl phosphate laser vaporization and transurethral resection of the prostate publication-title: J Urol – volume: 7 start-page: 384 year: 2008 end-page: 92 article-title: GreenLight HPS 120‐W laser for benign prostatic hyperplasia: comparative complications and technical recommendations publication-title: Eur Urol. Suppl. – volume: 22 start-page: 1519 year: 2008 end-page: 25 article-title: Comparison of photoselective vaporization of the prostate and transurethral resection of the prostate: a prospective nonrandomized bicenter trial with 2‐year follow‐up publication-title: J Endourol – volume: 48 start-page: 965 year: 2005 end-page: 72 article-title: Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi‐centre study of perioperative morbidity and early funcional outcome publication-title: Eur Urol – volume: 7 start-page: 361 year: 2008 end-page: 2 article-title: GreenLight HPS Laser therapy for BPH: clinical outcomes and surgical recommendations from the International GreenLight user (IGLU) group publication-title: Eur Urol Suppl – volume: 44 start-page: 856 year: 1994 end-page: 61 article-title: The optimization of laser prostatectomy part II: other lasing techniques publication-title: Urology – volume: 20 start-page: 580 year: 2006 end-page: 5 article-title: KTP laser versus transurethral resection: early results of a randomized trial publication-title: J Endourol – volume: 14 start-page: 21 year: 2004 end-page: 5 article-title: High‐power KTP laser prostatectomy: the new challenge to transurethral resection of the prostate publication-title: Curr Opin Urol – volume: 13 start-page: 34 year: 1995 end-page: 9 article-title: The Abrams–Griffiths nomogram publication-title: World J Urol – volume: 14 start-page: 3710 year: 2007 end-page: 4 article-title: Predictability of irritative voiding symptoms following phtoselective laser vaporization of the prostate publication-title: Can J Urol – volume: 172 start-page: 1404 year: 2004 end-page: 8 article-title: Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12‐month results from The First United States Multicenter Prospective Trial publication-title: J Urol – volume: 8 start-page: S24 issue: 3 year: 2006 end-page: 30 article-title: The next generation in laser treatments and the role of the GreenLight high‐performance system laser publication-title: Rev Urol – volume: 60 start-page: 734 year: 2011 end-page: 9 article-title: Green‐light HPS 120‐W laser vaporization versus transurethral resection of the prostate for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2‐year follow‐up publication-title: Eur Urol – volume: 102 start-page: 1432 year: 2008 end-page: 8 article-title: Comparison of potassium‐titanyl‐phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective nonrandomized two‐centre study publication-title: BJU Int – volume: 54 start-page: 902 year: 2008 end-page: 7 article-title: Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow‐up publication-title: Eur Urol – volume: 33 start-page: 771 year: 2009 end-page: 7 article-title: Photoselective vaporization of the prostate with Laser Greenlight HPS: current role, technical aspects and review of the literature publication-title: Actas Urol Esp – volume: 36 start-page: 190 year: 2010 end-page: 7 article-title: Photoselective vaporazotion of the prostate in men with a history of chronic oral anti‐coagulation publication-title: Int Braz J Urol – volume: 10 start-page: S2 year: 2007 end-page: 5 article-title: Current state of the art photoselective vaporization prostatectomy: laser therapy for benign prostatic hyperplasia publication-title: Prostate Cancer Prostatic Dis – volume: 163 start-page: 1730 year: 2000 end-page: 3 article-title: High power potassium‐titanyl‐phosphate laser vaporization prostatectomy publication-title: J Urol – volume: 14 start-page: 27 year: 2004 end-page: 9 article-title: Could the latest generation potassium titanyl phosphate lasers be the ones to make transurethral resection of the prostate an operation of historical interest only? publication-title: Curr Opin Urol – volume: 7 start-page: 378 year: 2008 end-page: 83 article-title: Outcome of GreenLight HPS 120‐W laser therapy in specific patient populations: those in retention, on anticoagulants, and with large prostates (≥80 mL) publication-title: Eur Urol Suppl – volume: 58 start-page: 349 year: 2010 end-page: 55 article-title: Green‐light HPS 120‐W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow‐up publication-title: Eur Urol – volume: 173 start-page: 158 year: 2005 end-page: 60 article-title: High power (80 W) potassium‐titanylphosphate laser vaporization of the prostate in 66 high risk patients publication-title: J Urol – volume: 51 start-page: 1031 year: 2007 end-page: 41 article-title: Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation publication-title: Eur Urol – volume: 7 start-page: 363 year: 2008 end-page: 9 article-title: Historical aspects of laser therapy for benign prostatic hyperplasia publication-title: Eur Urol Suppl – volume: 75 start-page: 1015 year: 2010 end-page: 22 article-title: Systematic review and meta‐analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction publication-title: Urology – volume: 69 start-page: 859 year: 2007 end-page: 63 article-title: Influence of bladder contractility on short‐term outcomes of high‐power potassium‐titanyl‐phosphate photoselective vaporization of the prostate publication-title: Urology – ident: e_1_2_7_29_2 doi: 10.1097/01.ju.0000128803.04158.76 – ident: e_1_2_7_12_2 doi: 10.1016/j.eururo.2008.05.003 – ident: e_1_2_7_13_2 doi: 10.1016/j.urology.2007.01.042 – ident: e_1_2_7_28_2 doi: 10.1016/j.eururo.2008.05.003 – ident: e_1_2_7_19_2 doi: 10.1016/j.urology.2009.08.015 – ident: e_1_2_7_21_2 doi: 10.1590/S1677-55382010000200009 – ident: e_1_2_7_7_2 doi: 10.1016/j.eururo.2005.07.001 – ident: e_1_2_7_9_2 doi: 10.1111/j.1464-410X.2008.07905.x – ident: e_1_2_7_31_2 doi: 10.1016/S0090-4295(94)80170-3 – ident: e_1_2_7_17_2 doi: 10.1097/01.ju.0000139541.68542.f6 – ident: e_1_2_7_6_2 doi: 10.1038/sj.pcan.4500949 – ident: e_1_2_7_8_2 doi: 10.1089/end.2006.20.580 – volume: 173 start-page: 158 year: 2005 ident: e_1_2_7_20_2 article-title: High power (80 W) potassium‐titanylphosphate laser vaporization of the prostate in 66 high risk patients publication-title: J Urol doi: 10.1097/01.ju.0000146631.14200.d4 – ident: e_1_2_7_11_2 doi: 10.1016/j.urology.2007.09.017 – volume: 14 start-page: 3710 year: 2007 ident: e_1_2_7_30_2 article-title: Predictability of irritative voiding symptoms following phtoselective laser vaporization of the prostate publication-title: Can J Urol – ident: e_1_2_7_14_2 doi: 10.1002/nau.10066 – ident: e_1_2_7_5_2 doi: 10.1097/00042307-200401000-00006 – ident: e_1_2_7_4_2 doi: 10.1097/00042307-200401000-00005 – ident: e_1_2_7_24_2 doi: 10.1016/j.eururo.2006.08.006 – ident: e_1_2_7_16_2 doi: 10.1016/S0022-5347(05)67530-1 – ident: e_1_2_7_10_2 doi: 10.1089/end.2007.0321 – ident: e_1_2_7_23_2 doi: 10.1016/j.eursup.2007.11.004 – ident: e_1_2_7_27_2 doi: 10.1016/j.eururo.2011.05.043 – ident: e_1_2_7_15_2 doi: 10.1007/BF00182664 – volume: 33 start-page: 771 year: 2009 ident: e_1_2_7_18_2 article-title: Photoselective vaporization of the prostate with Laser Greenlight HPS: current role, technical aspects and review of the literature publication-title: Actas Urol Esp – ident: e_1_2_7_2_2 doi: 10.1016/j.eursup.2008.01.014 – ident: e_1_2_7_26_2 doi: 10.1016/j.eururo.2010.05.026 – volume: 8 start-page: S24 issue: 3 year: 2006 ident: e_1_2_7_3_2 article-title: The next generation in laser treatments and the role of the GreenLight high‐performance system laser publication-title: Rev Urol – ident: e_1_2_7_22_2 doi: 10.1016/j.eursup.2008.01.013 – ident: e_1_2_7_25_2 doi: 10.1016/j.eursup.2008.01.016 |
| SSID | ssj0014665 |
| Score | 2.319352 |
| Snippet | Study Type – Therapy (RCT)
Level of Evidence 1b
What's known on the subject? and What does the study add?
Photovaporization of the prostate (PVP) is now... What's known on the subject? and What does the study add? Photovaporization of the prostate (PVP) is now challenging TURP as the standard treatment for lower... |
| SourceID | proquest pubmed pascalfrancis crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1184 |
| SubjectTerms | Aged Biological and medical sciences Double-Blind Method GreenLight laser Humans Laser Therapy Male Medical sciences Middle Aged Nephrology. Urinary tract diseases photovaporization prostate Prostate - surgery Prostatic Hyperplasia - physiopathology Prostatic Hyperplasia - surgery Transurethral Resection of Prostate urodynamic Urodynamics |
| Title | GreenLight HPS™ 120‐W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2‐year randomized double‐blind prospective urodynamic investigation |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10878.x https://www.ncbi.nlm.nih.gov/pubmed/22257240 https://www.proquest.com/docview/1081873397 |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1464-410X dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-4096 databaseCode: ABDBF dateStart: 19990101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1464-410X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-4096 databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1464-4096 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1464-410X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014665 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pa9RAFB-kBxFE6_-1WkbwoIcsmcxsJhEvVSxLaUXUxb2F-UuXdpNlNym2p0L9AH6G3v1S_SS-mcluSemhiLeQ5D3y8t6b-b3k_UHoNZE2VlxBpKqZiRhoPcqVJlHGrIYlUwLIcIHi3ud0OGI748G4zX9ytTChP8Tqg5vzDL9eOwcXcnHVyVnESDwOnThJnPGs7_AkoamPrr6uOknBrX6qZCAB2N5N6rmWUWenujsTC3hpNky7uA6OdtGt356276ODpWAhK-Wg39Syr06u9Hz8P5Kvo3stisVbweweoFumfIhu77X_6R-hPz6dZ9cF_nj45dvFr3NMkvji9PcPDGjdzPGRANzfloDiowWu3ZbZzE29Pwe-riTK11vgymJAqHjmalMAFeM371NgczbdffsOC5wAx2NwVQzUuppOTozGumrkoYELEgTVnrItJsUNbBbHpZhOFJ5cthepysdotP3p-8dh1A6GiBToMYuMSJnItaE0ToQWMVWMJdYwkhBBmc6MTQcKom-juAVd53EumNR2wKwaMJVb-gStlVVpniHMuOI8jXMKfFgGYAviMZvKRFPDdSxYD_GlERSq7ZruhnccFp3oiRVOG4XTRuG1UfzsIbKinIXOITeg2ezY2YowAdgNSDLroVdLwytgHXA_d0RpqmbhOJCMU4CXPfQ0WOQlNSzaHKAbCOPt6sbPU3zYGfnD5_9MuYHuwPkk5D--QGv1vDEvAcfVctN76F-4nj6L |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQIgES4g1bHouROMAhlZ24cYK48FqVpV0h2IreIscPUW2bVG2yYveEBD-A38CdP7W_hLGddpXVHlaIW5RkRpnMjP2N7ZlB6CnNDZFcQqSqmA4YaD1IpaJBwoyCITMHkGEDxeFu3B-xnXFv3LQDsrkwvj7EesHNeoYbr62D2wXp017OAkbJ2JfipCThSRcA5UW4T6yJv_20riUF77q-kp4GgHv7WM-ZnFpz1dW5WMJvM77fxVmAtI1v3QS1fR1NV6L5cyn73brKu_LoVNXH_yT7DXStAbL4lbe8m-iCLm6hS8Nmq_42-uNO9Axs7I_7Hz8f__yNaUiOv__6ggGw6wU-EAD9myxQfLDElZ0164Wuvi6Ar82KcikXuDQYQCqe2_QUAMb42csY2PyYDZ6_wAKHwPEQvBUDtSpnkyOtsCrrfKrhQQ6SKkfZ5JPiGuaLw0LMJhJPTiqMlMUdNNp-t_emHzS9IQIJikwCLWImUqWjiIRCCRJJxkKjGQ2piJhKtIl7EgJwLbkBZackFSxXpseM7DGZmugu2ijKQm8izLjkPCZpBHxYAngLQjIT56GKNFdEsA7iKyvIZFM43fbvmGatAIplVhuZ1UbmtJF96yC6ppz74iHnoNlqGdqaMATkDWAy6aAnK8vLYCiw-zui0GW9tBxowiNAmB10z5vkCTWM2xzQGwjjDOvc35O93hm5y_v_TPkYXe7vDQfZ4P3uhwfoCrwT-uOQD9FGtaj1I4B1Vb7l3PUvl6xCrA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hVqqQEG9KKLSLxAEOjvwYe23EBWijUNKqAiJys9b7EBGJHSV2RXtCgh_Ab-DOn-ovYXbtpHLVQ4W4WbJn5PU89hvvPAh55mXaFUxgpCpBOYBSdxIhPScGLdFlZggyTKB4cBj1h7A_CkfNOCBTC1P3h1j9cDOWYf21MXA1k_qilYMDnjuqW3F6bsziLgLKdQiT2OT37X5Y9ZLCZ-1cyZoGgXs7redSTq296saML_Cz6XrexWWAtI1v7QbVu0Umy6XVeSlfu1WZdcXpha6P_2ntt8nNBsjS17Xm3SHXVH6XbBw0R_X3yB-b0TMwsT_tH308-_mber579v3XZ4qAXc3pMUfo31SB0uMFLc2uWc1V-WWOfE1VlC25oIWmCFLpzJSnIDCmz19FyObHdPDiJeXUR44naK0UqWUxHZ8qSWVRZROFNzJcqbSUTT0prXC_OMn5dCzo-LzDSJHfJ8Pe3qe3faeZDeEIFGTsKB4BT6QKAtfnkruBAPC1As_3eAAyVjoKBQbgSjCNwk7chEMmdQhahCASHTwga3mRq4eEAhOMRW4SIB-IEW9hSKajzJeBYtLl0CFsqQWpaBqnm_kdk7QVQEFqpJEaaaRWGum3DvFWlLO6ecgVaLZbirYi9BF5I5iMO-TpUvNSdAXmfIfnqqgWhoMXswARZods1ip5To1-myF6w8VYxbry-6Rv9of28tE_U-6QjaPdXjp4d_h-i1zHR_w6G_IxWSvnlXqCqK7Mtq21_gXllkIw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GreenLight+HPS%E2%84%A2+120-W+laser+vaporization+vs+transurethral+resection+of+the+prostate+%28%3C60+mL%29%3A+a+2-year+randomized+double-blind+prospective+urodynamic+investigation&rft.jtitle=BJU+international&rft.au=Pereira-Correia%2C+Jo%C3%A3o+Antonio&rft.au=de+Moraes+Sousa%2C+Karlo+Danilson&rft.au=Santos%2C+Jo%C3%A3o+Bosco+Pinheiro&rft.au=de+Morais+Perp%C3%A9tuo%2C+Daniel&rft.date=2012-10-01&rft.issn=1464-410X&rft.eissn=1464-410X&rft.volume=110&rft.issue=8&rft.spage=1184&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10878.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |